About Lawley Pharmaceuticals

Lawley Pharmaceuticals Pty Ltd.

Lawley Pharmaceuticals is a privately owned pharmaceutical company whose focus is on the transdermal administration of the naturally occurring hormones testosterone, progesterone and oestradiol.

Founded in 1995 by pharmacist Michael Buckley, Lawley Pharmaceuticals has grown to become a world leader in research and development of transdermal hormone preparations.

As the principal of Lawley Pharmaceuticals Mr. Buckley has presided over the development, research, clinical trial program, regulatory process, development and marketing of the company. Mr. Buckley is a director of Lawley Pharmaceuticals Ltd, Octagon Enterprises Pty Ltd and Pro-Gest Pty Ltd.

Product Range

The Lawley Pharmaceuticals portfolio of products includes:

AndroFeme<sup>®</sup> ProFeme<sup>®</sup> AndroForte<sup>®</sup> Natragen

Clinical Studies & Trials

Completed Clinical Trials

The following clinical trials include:

  1. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women.
    Wren BG et al. Climacteric 2000 3:155–160.

    Download Medical Paper (126kb)

  2. Distribution and metabolism of topically applied progesterone in a rat model.
    Waddell B and O'Leary PJ. J Ster Biochem & Mol Biol. 80 (2002) 449-455.

    Download Medical Paper (94kb)

  3. Plasma and saliva concentrations of progesterone in pre- and postmenopausal women after topical application of progesterone cream.
    O'Leary PJ et al. Presented at the Annual Congress of the Australian Menopause Society held in Perth, Australia in October 1997.

    Download Medical Paper (45kb)

  4. Long-term pharmacokinetics and clinical efficacy of ANDROMEN®FORTE 5% cream for androgen replacement in hypogonadal men.
    Handelsman DJ et al. ANZAC Research Institute, Department of Andrology, Concord Hospital, Sydney, 2004.

    Download Medical Paper (1.8mb)

  5. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women.
    Goldstat R et al. Menopause 2003; 10 (5): 390-398.

    Download Medical Paper (355kb)

  6. The pharmacokinetics pilot study of ANDRO-FEME® 1% testosterone cream following two-week, once-daily application in testosterone deficient women.
    Eden JA et al. Presented at the 4th Annual Congress of the Australasian Menopause Society held in Adelaide 5-7th November 2000.

    Download Medical Paper (74kb)

  7. A double-blind, randomized, placebo-controlled trial of the effect of testosterone cream on the sexual motivation of menopausal hysterectomized women with hypoactive sexual desire disorder.
    El-Hage et al Climacteric 2007; 10: 335-343.

    Download Medical Paper (186kb)

  8. Pharmacokinetics Of Andromen Forte 5% Cream: A Dose Finding Study.
    Kelleher S et al. ANZAC Research Institute, Department of Andrology, Concord Hospital, Sydney, 2002.

    Download Medical Paper (177kb)

Lawley Pharmaceuticals has established strong links with centres of medical research excellence including:

  • The Barbara Gross Medical Research Institute, Royal Hospital for Women, Sydney, Australia
  • The Jean Hailes Medical Research Foundation, Clayton, Melbourne, Australia
  • The Menopause Unit, King Edward Memorial Hospital, Perth, Australia
  • Royal Perth Hospital, Dept of Endocrinology, Perth, Australia
  • Prince Henry Institute of Medical Research, Clayton, Melbourne, Australia
  • ANZAC Medical Research Institute, Concord Hospital, Sydney, Australia
  • St George Hospital, Kogarah, Sydney, Australia
  • Prince Henry's Institute of Medical Research, Melbourne, Australia
  • McCusker Foundation for Alzheimer's Disease Research, Nedlands, Perth, Australia
  • Neuroscience Centre, Siloam Gleneagles Hospital Lippo Karawaci, Indonesia
  • Royal Adelaide Hospital, South Australia, Australia
  • PARC - Pain and Analgesic Research Centre, South Australia, Australia
  • NERI - New England Research Institutes Watertown MA, USA